医療従事者の為の最新医療ニュースや様々な情報・ツールを提供する医療総合サイト

The Healthcare+ Expo Taiwan Continues to Lead a Medical Innovation Hub With Its Strength in Digital Health, Health Tech and Medicine

2019年07月30日 PM10:05
このエントリーをはてなブックマークに追加


 

TAIPEI, Taiwan

Following the success last year, the Healthcare+ Expo sees a rapid growth in size and significance of procurement, networking and marketing. The Expo is now regarded as a primary event in Asia, attracting global participation from more than 5,000 buyers, 500 enterprises, 60 high-profile speakers and 100 professional institutions to come to Taipei on 5-8 December 2019.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190730005084/en/

Where key opinion leaders go and business grows

Exhibitors this year have a strong presence in medical AI, health tech and medicine. World-class medical centres, IT giants, international brands for medical devices and innovative startups congregate at the Expo to impress audiences with advanced health tech and life-saving medical development. In addition to that, the Expo sets the theme to digital health utilising AI, IoT, cloud computing and robotics, new technology for cancer treatment, precision health and smart hospitals in response to robust market demands.

As part of the Expo programmes, MEDTEX Summit Asia brings together 10 top venture capital firms, global AI pioneers, a Nobel Prize winner and multinational pharmaceutical executives to project their views on futuristic trends of healthcare. Visitors having business agendas can then anticipate fruitful results gained in conferences, match-making sessions and roadshows, as well as taking home with high quality market insights.

Why Taiwan matters to healthcare industry

Taiwan has a competitive edge as it is situated the heart of Asia, with proximity and commercial links to emerging economics, and a home to leading electronics manufacturers and well-connected supply chains. Coupling with its strength in tech, the healthcare system here provides not only a universal coverage for every citizen but a massive amount of data collected over years that paves the way for Taiwan to excel in wider healthcare business competitions.

The Expo thus invites those who are or will be in healthcare business, to save the date, come prepared and stay connected wherever they are. Visitors with interest in the Expo are suggested booking a place online beforehand (click here); early bird offers are available now until 30 September.

Register now

Expo in detail

View source version on businesswire.com: https://www.businesswire.com/news/home/20190730005084/en/

CONTACT

Research Centre for Biotechnology and Medicine Policy

Gordon Shen PhD. +886 2 2655 7888 Ext.630 chinhuishen@rbmp.org.tw

Miss Silvia Fan +886 2 2655 7888 Ext.649 silvia@rbmp.org.tw

David Yang PhD. +886 2 2655 7888 Ext.627 fmyang@rbmp.org.tw

Related Posts Plugin for WordPress, Blogger...

同じカテゴリーの記事 

  • Daiichi Sankyo Announces Clinical Research Collaboration to Evaluate DS-1062 in Combination with KEYTRUDA® (pembrolizumab) in Metastatic Non-Small Cell Lung Cancer
  • ENHERTU® Significantly Improved Tumor Response Rate and Overall Survival in HER2 Positive Metastatic Gastric Cancer in Pivotal Phase 2 DESTINY-Gastric01 Trial
  • ENHERTU® Demonstrated Meaningful Clinical Activity in Patients with HER2 Mutant Non-Small Cell Lung Cancer in Interim Analysis of Phase 2 DESTINY-Lung01 Trial
  • ENHERTU® Achieved a Tumor Response Rate of 45.3% in Patients with HER2 Positive Metastatic Colorectal Cancer in Phase 2 DESTINY-CRC01 Trial
  • Takeda to Present Data from the ICLUSIG® (ponatinib) Clinical Trial Program that Could Prove Practice-Changing for the Treatment of Chronic-Phase CML